REDEYE

OncoZenge

Research Note







Performance VS OMXS30



Share Information

Share Price SEK	**6.22**
Number of shares (M)	**11.7**
Marketplace	**First North Stockholm**
CEO	**Stian Kildal**
Chairman	**Daniel Ehrenstråhle**

Key Stats

Market Cap	**72.8 MSEK**
Entprs. Value (EV)	**71.5 MSEK**
Net Debt (2025Q1)	**-1.3 MSEK**
30 Day Avg Vol	**33 K**
Dividend Yield	**N/A**

Top Holders

Name	Ownership
Niclas Holmgren	12.5%
Linc AB	9.99%
Andreas Adnan Özbek	6.51%
Avanza Pension	4.27%
Kalle Holmgren	3.41%
Stian Kildal	2.99%
Svenska Mäklarkontoret AB	2.77%
Jimmy Mattias Olsson	2.67%
Nordnet Pensionsförsäkring	2.66%
Dan Mikael Joacim Friberg	2.13%

OncoZenge: Engages LINK Medical for feasibility study

Redeye comments on OncoZenge's engagement of LINK Medical to conduct a feasibility study ahead of its European phase III trial for BupiZenge. We view this as a strategically important step in the company's clinical execution plan, aimed at optimizing trial site selection and recruitment timelines in key European markets.

OncoZenge recently announced that it has engaged LINK Medical to conduct a feasibility study ahead of its upcoming European phase III trial of BupiZenge. We believe that this marks a meaningful step forward in preparations for the pivotal trial. The primary goal of the feasibility study is to identify and secure high-quality clinical sites across Germany, Denmark, Norway, and Sweden. These are regions that are well-regarded for robust clinical trial infrastructure and efficient regulatory pathways. Beyond simply mapping site availability, the study will provide important decision-making data regarding patient recruitment potential, such as the expected recruitment pace and the number of eligible patients per site per week. As such, this feasibility study is not just a routine prelude to trial setup, it is a strategically important task aimed at de-risking the study timeline and strengthening the foundation for a successful European approval path.

By initiating this feasibility process early and during the summer months, OncoZenge is working to stay ahead of the timeline and avoid unnecessary delays later in the process. The company's decision to engage LINK Medical, a CRO with a strong track record in Northern Europe, appears both strategic and practical. LINK's pre-existing relationships with key opinion leaders (KOLs) and its embedded knowledge of the local regulatory and operational environment could streamline the startup phase of multinational trials. Should LINK deliver successfully, we believe that it would also make them a logical partner for managing the full phase III study, ensuring continuity and executional consistency.

While modest in scope, the feasibility study supports OncoZenge's broader clinical and regulatory roadmap. We are encouraged to see the company's proactive planning and structured approach to trial execution.

Redeye Equity Analysts

Kevin Sule
kevin.sule@redeye.se

More research on OncoZenge

Scan the QR code to access all Redeye publications and research tools regarding OncoZenge.

redeye.se/company/oncozenge

Disclaimer

Important information

Redeye AB ("Redeye" or "the Company") is a specialist financial advisory boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the technology and life science sectors. We provide services within Corporate Broking, Corporate Finance, equity research and investor relations. Our strengths are our award-winning research department, experienced advisers, a unique investor network, and the powerful distribution channel redeye.se. Redeye was founded in 1999 and since 2007 has been subject to the supervision of the Swedish Financial Supervisory Authority.
Redeye is licensed to; receive and transmit orders in financial instruments, provide investment advice to clients regarding financial instruments, prepare and disseminate financial analyses/recommendations for trading in financial instruments, execute orders in financial instruments on behalf of clients, place financial instruments without position taking, provide corporate advice and services within mergers and acquisition, provide services in conjunction with the provision of guarantees regarding financial instruments and to operate as a Certified Advisory business (ancillary authorization).

Limitation of liability

This document was prepared for information purposes for general distribution and is not intended to be advisory. The information contained in this analysis is based on sources deemed reliable by Redeye. However, Redeye cannot guarantee the accuracy of the information. The forward-looking information in the analysis is based on subjective assessments about the future, which constitutes a factor of uncertainty. Redeye cannot guarantee that forecasts and forward-looking statements will materialize. Investors shall conduct all investment decisions independently. This analysis is intended to be one of a number of tools that can be used in making an investment decision. All investors are therefore encouraged to supplement this information with additional relevant data and to consult a financial advisor prior to an investment decision. Accordingly, Redeye accepts no liability for any loss or damage resulting from the use of this analysis.

Potential conflict of interest

Redeye's research department is regulated by operational and administrative rules established to avoid conflicts of interest and to ensure the independence of its analysts. The following applies:

- For companies that are the subject of Redeye's research analysis, the applicable rules include those established by the Swedish Financial Supervisory Authority pertaining to investment recommendations and the handling of conflicts of interest. Furthermore, Redeye employees are not allowed to trade in financial instruments of the company in question, from the date Redeye publishes its analysis plus one trading day after this date.
- An analyst may not engage in corporate finance transactions without the explicit approval of management and may not receive a remuneration directly linked to such transactions.
- Readers of these reports should assume that Redeye may have received or will receive remuneration from the company/companies cited in the report for the performance of financial advisory services. Such remuneration is of a predetermined amount and is not dependent on the content of the research.

Redeye's research coverage

Redeye's research analyses consist of case-based analyses, which imply that the frequency of the analytical reports may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Recommendation structure

Redeye does not issue any investment recommendations for fundamental analysis. However, Redeye has developed a proprietary analysis and rating model, Redeye Rating, in which each company is analyzed and evaluated. This analysis aims to provide an independent assessment of the company in question, its opportunities, risks, etc. The purpose is to provide an objective and professional set of data for owners and investors to use in their decision-making.

Duplication and distribution